WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 200185
Description: AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor AMG 208 inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity, which may result in cell growth inhibition in tumors that overexpress c-Met. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase, plays an important role in epithelial cell proliferation and has been shown to be overexpressed in a variety of cancers.
MedKoo Cat#: 200185
Chemical Formula: C22H17N5O2
Exact Mass: 383.13822
Molecular Weight: 383.4
Elemental Analysis: C, 68.92; H, 4.47; N, 18.27; O, 8.35
Synonym: AMG208; AMG 208; AMG-208.
IUPAC/Chemical Name: 4-[(6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methoxy]-7-methoxyquinoline
InChi Key: HEAIZQNMNCHNFD-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3
SMILES Code: COC1=CC=C2C(OCC3=NN=C4C=CC(C5=CC=CC=C5)=NN43)=CC=NC2=C1
AMG-208 is currently developed and investigated by Amgen as an anticancer drug candidate. Amgen-208 inhibits both ligand-dependent and ligand-independent c-Met activation. As of 2010, Amgen is in phase 1 clinical trials. (source: http://clinicaltrials.gov/ct2/show/NCT00813384).